The three-dimensional configuration of the ester heterocycle is basically the same as that of the carbocycle. Compound: (4-(Pyridin-4-yl)phenyl)methanol(SMILESS: OCC1=CC=C(C2=CC=NC=C2)C=C1,cas:217192-22-8) is researched.Reference of 1-(Bromomethyl)-4-ethylbenzene. The article 《Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl》 in relation to this compound, is published in Journal of Medicinal Chemistry. Let’s take a look at the latest research on this compound (cas:217192-22-8).
EP2 receptor agonists are expected to be effective ocular hypotensive agents; however, it has been suggested that agonism to other EP receptor subtypes may lead to undesirable effects. Through medicinal chem. efforts, we identified a scaffold bearing a (pyridin-2-ylamino)acetic acid moiety as a promising EP2-selective receptor agonist. (6-((4-(Pyrazol-1-yl)benzyl)(pyridin-3-ylsulfonyl)aminomethyl)pyridin-2-ylamino)acetic acid 13ax (omidenepag, OMD) exerted potent and selective activity toward the human EP2 receptor (h-EP2). Low doses of omidenepag iso-Pr (OMDI), a prodrug of 13ax, lowered intraocular pressure (IOP) in ocular normotensive monkeys. OMDI was selected as a clin. candidate for the treatment of glaucoma.
Here is just a brief introduction to this compound(217192-22-8)SDS of cas: 217192-22-8, more information about the compound((4-(Pyridin-4-yl)phenyl)methanol) is in the article, you can click the link below.
Reference:
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N2 | ChemSpider